CORCEPT THERAPEUTICS INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
CORCEPT THERAPEUTICS INC (CORT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-06.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2017-03-06
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2016 was $0.00.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2014 was $249.00K, a 34.99% decline from fiscal 2013.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2013 was $383.00K, a 53.69% decline from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-06 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-06 |
| 2014-12-31 | $249.00K 10-K · filed 2017-03-06 |
| 2013-12-31 | $383.00K 10-K · filed 2016-03-10 |
| 2012-12-31 | $827.00K 10-K · filed 2015-03-13 |
| 2011-12-31 | $2.12M 10-K · filed 2014-03-14 |
| 2010-12-31 | $1.67M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |